Botulism and guanidine. Ten years later

Area of Science:

• Neurology
• Pharmacology

Background:

• Guanidine hydrochloride was introduced in 1968 as an adjunctive therapy for botulism.
• Previous reports indicate variable efficacy, with 39 cases showing benefit and 13 showing none.

Observation:

• Two new cases of botulism treated with guanidine hydrochloride were analyzed.
• Improvements were most pronounced in ocular muscles and least in respiratory muscles.
• No serious side effects were observed with short-term guanidine therapy.

Findings:

• Electrophysiological studies demonstrated an increased amplitude of evoked muscle-action potentials post-guanidine administration.
• The observed clinical improvements align with previous findings regarding muscle group specificity.

Implications:

• Guanidine hydrochloride remains a potential therapeutic option for botulism, particularly for ocular muscle involvement.
• Further research may elucidate optimal usage and patient selection for guanidine therapy in botulism.
• The safety profile supports its consideration in short-term botulism treatment regimens.